Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody Positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository.

Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, Banzato A, Pengo V, Ugarte A, Gerosa M, Ji L, Efthymiou M, Branch DW, de Jesus GR, Tincani A, Belmont HM, Fortin PR, Petri M, Rodriguez E, Pons-Estel GJ, Knight JS, Atsumi T, Willis R, Zuily S, Tektonidou MG; TheBehalf of APS ACTION.

Arthritis Care Res (Hoboken). 2018 Apr 18. doi: 10.1002/acr.23584. [Epub ahead of print]

PMID:
29669399
2.

Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study.

Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Tektonidou MG.

Semin Arthritis Rheum. 2017 Oct 23. pii: S0049-0172(17)30493-6. doi: 10.1016/j.semarthrit.2017.10.015. [Epub ahead of print]

PMID:
29150207
3.

Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016.

Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM.

Ann Rheum Dis. 2017 Dec;76(12):2009-2016. doi: 10.1136/annrheumdis-2017-211663. Epub 2017 Aug 9. Review. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

PMID:
28794077
4.

Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.

Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, Gonzalez E, Knight JS, Uthman I, Willis R, Zhang Z, Wahl D, Zuily S, Tektonidou MG; APS ACTION.

Lupus. 2018 Mar;27(3):399-406. doi: 10.1177/0961203317724219. Epub 2017 Aug 1.

PMID:
28764618
5.

Methodological Quality of Studies of Endstage Renal Disease in Lupus Nephritis, 1970 to 2015.

Tektonidou MG, Ward MM.

J Rheumatol. 2017 May;44(5):626-630. doi: 10.3899/jrheum.160546. Epub 2017 Feb 15. Review.

6.

Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis.

Tektonidou MG, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Protogerou A.

Autoimmun Rev. 2017 Mar;16(3):308-312. doi: 10.1016/j.autrev.2017.01.009. Epub 2017 Jan 29.

PMID:
28147263
7.

Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012.

Tektonidou MG, Wang Z, Ward MM.

Arthritis Rheumatol. 2016 Nov;68(11):2680-2685. doi: 10.1002/art.39758.

8.

Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis.

Tektonidou MG, Dasgupta A, Ward MM.

Arthritis Rheumatol. 2016 Jun;68(6):1432-41. doi: 10.1002/art.39594. Review.

9.

Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging.

Mavrogeni SI, Sfikakis PP, Kitas GD, Kolovou G, Tektonidou MG.

Semin Arthritis Rheum. 2016 Apr;45(5):611-6. doi: 10.1016/j.semarthrit.2015.09.005. Epub 2015 Oct 8. Review.

PMID:
26616201
10.

Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011.

Tektonidou MG, Wang Z, Dasgupta A, Ward MM.

Arthritis Care Res (Hoboken). 2015 Aug;67(8):1078-85. doi: 10.1002/acr.22575.

11.

Women's health and fertility, family planning and pregnancy in immune-mediated rheumatic diseases: a report from a south-eastern European Expert Meeting.

Ntali S, Damjanov N, Drakakis P, Ionescu R, Kalinova D, Rashkov R, Malamitsi-Puchner A, Mantzaris G, Michala L, Pamfil C, Rednic S, Tektonidou MG, Tsiodras S, Vassilopoulos D, Vojinovic J, Bertsias GK, Boumpas DT.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):959-68. Epub 2014 Nov 7. Review.

PMID:
25436516
12.

Asymptomatic bacteriuria in women with autoimmune rheumatic disease: prevalence, risk factors, and clinical significance.

Georgiadou SP, Gamaletsou MN, Mpanaka I, Vlachou A, Goules AV, Ziogas DC, Syriou V, Tektonidou MG, Kaltsas G, Manoussakis MN, Sipsas NV.

Clin Infect Dis. 2015 Mar 15;60(6):868-74. doi: 10.1093/cid/ciu938. Epub 2014 Nov 24.

PMID:
25422387
13.

Identification and treatment of APS renal involvement.

Tektonidou MG.

Lupus. 2014 Oct;23(12):1276-8. doi: 10.1177/0961203314538687.

PMID:
25228725
14.

14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.

Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Willis R, Lockshin MD.

Autoimmun Rev. 2014 Jun;13(6):685-96. doi: 10.1016/j.autrev.2014.01.053. Epub 2014 Jan 24. Review.

PMID:
24468415
15.

Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS).

Cuadrado MJ, Bertolaccini ML, Seed PT, Tektonidou MG, Aguirre A, Mico L, Gordon C, Ruiz-Irastorza G, Egurbide MV, Gil A, Espinosa G, Houssiau F, Rahman A, Martin H, McHugh N, Galindo M, Akil M, Amigo MC, Murru V, Khamashta MA.

Rheumatology (Oxford). 2014 Feb;53(2):275-84. doi: 10.1093/rheumatology/ket313. Epub 2013 Oct 4.

PMID:
24097288
16.

Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis.

Konsta M, Bamias G, Tektonidou MG, Christopoulos P, Iliopoulos A, Sfikakis PP.

Rheumatology (Oxford). 2013 Mar;52(3):448-51. doi: 10.1093/rheumatology/kes316. Epub 2012 Nov 30.

PMID:
23204549
17.

Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis.

Fragiadaki K, Tektonidou MG, Konsta M, Chrousos GP, Sfikakis PP.

J Rheumatol. 2012 Jan;39(1):60-2. doi: 10.3899/jrheum.110617. Epub 2011 Dec 1.

PMID:
22133618
18.

Validation of new biomarkers in systemic autoimmune diseases.

Tektonidou MG, Ward MM.

Nat Rev Rheumatol. 2011 Nov 1;7(12):708-17. doi: 10.1038/nrrheum.2011.157. Review.

19.
20.

Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations.

Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, Vadya S, Adrogué HE, Solomon M, Zandman-Goddard G, Shoenfeld Y.

Lupus. 2011 Feb;20(2):174-81. doi: 10.1177/0961203310395052.

PMID:
21303834
21.

Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions.

Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, Vadya S, Adrogué HE, Solomon M, Zandman-Goddard G, Shoenfeld Y.

Lupus. 2011 Feb;20(2):165-73. doi: 10.1177/0961203310395051.

PMID:
21303833
22.

Presence of other autoimmune diseases in subjects with autoimmune thyroid disease.

Tektonidou MG.

Am J Med. 2010 Oct;123(10):e23; author reply e25. doi: 10.1016/j.amjmed.2010.03.030. No abstract available.

PMID:
20920677
23.

Sleep disturbances in adults with arthritis: prevalence, mediators, and subgroups at greatest risk. Data from the 2007 National Health Interview Survey.

Louie GH, Tektonidou MG, Caban-Martinez AJ, Ward MM.

Arthritis Care Res (Hoboken). 2011 Feb;63(2):247-60. doi: 10.1002/acr.20362.

24.

Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases.

Tektonidou MG, Ward MM.

Arthritis Res Ther. 2010;12(5):R179. doi: 10.1186/ar3143. Epub 2010 Sep 27.

25.

MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab.

Tektonidou MG.

Lupus. 2010 Sep;19(10):1243-5. doi: 10.1177/0961203310367659. Epub 2010 May 25.

PMID:
20501524
26.

Measures of psychological distress in patients with arthritis: comment on the article by Fuller-Thomson and Shaked.

Caban-Martinez AJ, Louie GH, Ward MM, Tektonidou MG.

Arthritis Care Res (Hoboken). 2010 Jan 15;62(1):140-1; author reply 141-2. doi: 10.1002/acr.20030. No abstract available.

27.

Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.

Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV.

Emerg Infect Dis. 2009 Jun;15(6):956-9. doi: 10.3201/eid1506.090101. Review.

28.

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM.

Arthritis Rheum. 2009 Jan 15;61(1):29-36. doi: 10.1002/art.24232.

29.

Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.

Tektonidou MG.

Clin Rev Allergy Immunol. 2009 Jun;36(2-3):131-40. doi: 10.1007/s12016-008-8112-z. Review.

PMID:
19048414
30.

Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS.

Tektonidou MG, Sotsiou F, Moutsopoulos HM.

J Rheumatol. 2008 Oct;35(10):1983-8. Epub 2008 Aug 1.

PMID:
18688914
31.

Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis.

Serelis J, Kontogianni MD, Katsiougiannis S, Bletsa M, Tektonidou MG, Skopouli FN.

Clin Rheumatol. 2008 Jun;27(6):795-7. doi: 10.1007/s10067-008-0855-7. Epub 2008 Feb 28.

PMID:
18305977
32.

Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?

Tektonidou MG, Skopouli FN.

Clin Rheumatol. 2008 Apr;27(4):541-2. Epub 2007 Oct 26.

PMID:
17963018
33.

Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution.

Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM.

Am J Med. 2007 Jul;120(7):636-42.

PMID:
17602939
34.

Neurological complications of infliximab.

Tektonidou MG.

J Rheumatol. 2007 Jan;34(1):237; author reply 237-8. No abstract available.

PMID:
17216701
35.

Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings.

Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM.

Arch Intern Med. 2006 Nov 13;166(20):2278-84.

PMID:
17101948
36.

Reiter's syndrome during intravesical BCG therapy for bladder carcinoma.

Tektonidou MG.

Clin Rheumatol. 2007 Aug;26(8):1368-9. Epub 2006 Aug 16.

PMID:
16912847
37.

Osteoarticular manifestations of antiphospholipid syndrome.

Tektonidou MG, Moutsopoulos HM.

Rheum Dis Clin North Am. 2006 Aug;32(3):523-35. Review.

PMID:
16880082
38.

Sustained 3-year remission after rituximab treatment in a patient with refractory Wegener's granulomatosis.

Tektonidou MG, Skopouli FN.

Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S103. No abstract available.

PMID:
16859607
39.

Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment.

Tektonidou MG, Serelis J, Skopouli FN.

Clin Rheumatol. 2007 Feb;26(2):258-60. Epub 2006 Jul 6.

PMID:
16683176
40.
41.

Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.

Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM.

Arthritis Rheum. 2004 Aug;50(8):2569-79.

42.

Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases.

Tektonidou MG, Anapliotou M, Vlachoyiannopoulos P, Moutsopoulos HM.

Ann Rheum Dis. 2004 Sep;63(9):1159-61.

43.

Immunologic factors in the pathogenesis of osteonecrosis.

Tektonidou MG, Moutsopoulos HM.

Orthop Clin North Am. 2004 Jul;35(3):259-63, vii. Review.

PMID:
15271533
44.

Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus.

Tektonidou MG, Vlachoyiannopoulos PG.

Lupus. 2003;12(9):723-4. No abstract available.

PMID:
14514139
45.

The successful use of i.v. gammaglobulin for Guillain-Barré syndrome following gold therapy in an RA patient.

Tektonidou MG, Skopouli FN.

Clin Exp Rheumatol. 2003 May-Jun;21(3):404-5. No abstract available.

PMID:
12846068
46.

Paravertebral leiomyosarcoma mimicking a chronic ongoing inflammatory process.

Tektonidou MG, Trakadas SI, Skopouli FN.

Clin Exp Rheumatol. 2003 Mar-Apr;21(2):237-8.

PMID:
12747283
47.

Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study.

Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM.

Rheumatology (Oxford). 2003 May;42(5):645-51.

PMID:
12709540
48.
49.

Comparison of evidence of treatment effects in randomized and nonrandomized studies.

Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J.

JAMA. 2001 Aug 15;286(7):821-30. Review.

PMID:
11497536
50.

Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome.

Tektonidou MG, Ioannidis JP, Moyssakis I, Boki KA, Vassiliou V, Vlachoyiannopoulos PG, Kyriakidis MK, Moutsopoulos HM.

Ann Rheum Dis. 2001 Jan;60(1):43-8.

Supplemental Content

Loading ...
Support Center